Deeplabs, a Spanish company that owns and manages private science and innovation districts, has completed the first half of 2024 with an investment of more than 200 million euros in life science and innovation hubs. Deeplabs currently manages two main districts: MASID in Madrid and BASID in Barcelona. The districts include three operational campuses: Tres Cantos and Fuencarral in Madrid, and Esplugues de Llobregat and Sant Joan Despí in Barcelona, the latter inaugurated earlier this year.
At the end of the first half of 2024, the districts totalled 150,000 sqm, with an 84% occupancy rate in spaces already operational and 21,000 sqm under development for new projects. More than 70 companies, including Bayer, GMV and Takeda, are located in these districts, employing 7,000 professionals with the capacity to reach up to 10,000.
The districts are undergoing constant evolution, with projects such as Micampus Wynwood in Fuencarral, Torre Caleido and Madrid Nuevo Norte in Madrid, as well as the future Hospital Clínic and Biocluster Southern Europe in Barcelona.
Javier de Pablo, co-CEO of Deeplabs, says: "The high occupancy of the spaces reflects the trust that companies are placing in our hubs. Companies not only want good workspaces, but also services that provide added value, space and belong to an ecosystem where synergies are generated and they have the capacity to grow".
According to a report by QBE Spain, the Life Science sector has contributed 8 billion euros to Spain's Gross Domestic Product (GDP), a record that underlines the growing importance of the industry. Deeplabs, as part of this ecosystem, aims to provide key spaces and resources for the development of both large corporations and startups.
Pilar Gil, co-CEO of Deeplabs, highlights: "We are focused on offering new lab spaces at both MASID and BASID to respond to the high demand in the life sciences sector with fully equipped spaces and management of high value-added scientific services".